UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.

The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.

The company didn't immediately respond to a request for comment from MT Newswires.

Shares of the company were up 13% in Thursday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 10.27, Change: +1.23, Percent Change: +13.61